**Abstract**

Recent advances in molecular therapies for Duchenne muscular dystrophy (DMD) require precise genetic diagnosis because most therapeutic strategies are mutation-specific. To understand more about the genotype-phenotype correlations of the DMD gene we performed a comprehensive analysis of the DMD mutational spectrum in a large series of families. Here we provide the clinical, pathological and genetic features of 576 dystrophinopathy patients. DMD gene analysis was performed using the MLPA technique and whole gene sequencing in blood DNA and muscle cDNA. The impact of the DNA variants on mRNA splicing and protein functionality was evaluated by *in silico* analysis using computational algorithms. DMD mutations were detected in 576 unrelated dystrophinopathy families by combining the analysis of exonic copies and the analysis of small mutations. We found that 471 of these mutations were large intragenic rearrangements. Of these, 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%). Small mutations were identified in 105 cases (18.2%), most being nonsense/frameshift types (75.2%). Mutations in splice sites, however, were relatively frequent (20%). In total, 276 mutations were identified, 85 of which have not been previously described. The diagnostic algorithm used proved to be accurate for the molecular diagnosis of dystrophinopathies. The reading frame rule was fulfilled in 90.4% of DMD patients and in 82.4% of Becker muscular dystrophy patients (BMD), with significant differences between the mutation types. We found that 58% of DMD patients would be included in single exon-exon skipping trials, 63% from strategies directed against multiexon-skipping exons 45 to 55, and 14% from PTC therapy. A detailed analysis of missense mutations provided valuable information about their impact on the protein structure.
Background

Dystrophinopathies are the most common forms of muscular dystrophy in childhood. They are caused by mutations in the X chromosome-linked DMD gene [OMIM: *300377] [1, 2]. DMD gene is the largest known human gene, spanning 2.22 Mb in the region Xp21, and it has 79 exons and 8 promoters. In addition, most of these small mutations are unique and one-third are sporadic. This gene encodes the protein called dystrophin, a key element in stabilizing the sarcolemma during muscle contraction [3]. There are two main phenotypes: Duchenne muscular dystrophy, a severe form that has an incidence of 1:3500 male births [OMIM # 310200], and Becker muscular dystrophy, a mild form with an incidence of 1:20000 male births, [OMIM # 300376]. One-third of the mutations are de novo [4]. Clinical severity depends on whether or not the reading frame of the gene is maintained: DMD is mostly caused by out-frame mutations while BMD is caused by in-frame mutations [5]. Mutations in the DMD gene can be associated with X-linked dilated cardiomyopathy, in which case patients present only with heart problems. [OMIM # 302045], [6].

Since the gene was discovered in 1986, many mutations have been described. Mutational studies have traditionally focused on the detection of exonic deletions, representing 65% of all mutations. The observation that some exons were more frequently deleted led to the implementation of multiplex PCR as a standard diagnostic method [7]. This technique can detect up to 98% of deletions, but it does not delimit the extent of the deletions or detect exonic duplications, which represent up to 10% of the mutations. Moreover, multiplex PCR is unable to detect mutations in carrier women. To detect duplications, it is necessary to analyse the number of exonic copies. The recent introduction of dosimetry methods based on PCR MLPA (multiplex ligation-dependent probe amplification) has significantly improved the detection of large intragenic rearrangements in the 79 exons that constitute the gene [8, 9].

The remaining mutations are small mutations and they account for approximately 25–30% of the molecular pathology of the DMD gene. The analysis of these small mutations has historically been a difficult task, mainly due to the gene’s size. The search for rapid and economical detection of these mutations led to the development of several techniques [10–13]. In recent years, the affordable cost of Sanger sequencing and the development of massive sequencing systems (Next Generation Sequencing, NGS) has made DMD gene analysis affordable. Flanigan and co-workers described a semi-automatic technique for direct sequencing of the 79 exons and flanking intron sequences in genomic DNA called SCAIP (single-condition amplification/internal first) [14]. This technique, that also detects deletions, has a higher sensitivity than the screening methods based on conformational analysis or heteroduplex. In 2007, Deburgrave et al. described another diagnostic strategy based on the use of muscle biopsy, combining protein analysis by Western-blotting and multiplex mutational study by direct sequencing of mRNA [15]. This technique is highly efficient, since the detection rate is almost 100% in patients with altered quantitative or qualitative Western-blot for dystrophin. Furthermore, it can detect virtually all types of mutations. It provides a comprehensive correlation between genotype and protein expression, helping to predict clinical phenotype. In this paper we describe 576 dystrophinopathy families and discuss the mutational spectrum associated with the DMD gene and its impact on the dystrophin structure.

Materials and Methods

Patients

Patients with DMD/BMD were grouped into four categories: Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), intermediate muscular dystrophy (IMD), and pure cardiac X-linked dilated cardiomyopathy (XLCM), based on clinical presentation, family
history, age of onset of symptoms, disease progression, and age of loss of ambulation (DMD <13, BMD ≥16, IMD ≥13 and XLCM <16). To avoid bias, we included only one case for each family. A histopathological study was performed prior to molecular analysis in all cases for which a muscle biopsy was available. Dystrophin expression was analysed using monoclonal antibodies against N-terminal epitopes (DYS3), rod domain (DYS1) and C-terminus (DYS2) (Novocastra, Newcastle upon Tyne, UK). Other sarcolemmal proteins, such as sarcoglycans α, β, γ and δ, caveolin-3, dysferlin, utrophin and emerin, were also analysed by IHC.

Written informed consent was obtained from all patients. In those cases where patients were minors, written informed consent was authorised and signed by their parents. Adult patients authorised and signed their own informed consent. The studies were approved by the Ethics Committee at Hospital de la Santa Creu I Sant Pau (HSPSC).

Genetic analysis

DNA from patients and their relatives was obtained from samples extracted from peripheral blood according to standard procedures. Before studying the small mutations, we analysed exonic deletions and duplications using MLPA of the 79 DMD exons (P034 and P035 Sauce Kit, MRC-Holland) following the manufacturer’s instructions. If a deletion of a single exon was identified, an alternative method was required (PCR, QF-PCR or real-time qPCR, exon sequencing) to rule out a point mutation, rare variant or polymorphism altering the normal MLPA pattern. Small mutations were detected in most patients by direct sequencing of the 79 exons and flanking intron regions by SCAIP [14]. When muscle tissue was available, mutational analysis was performed on cDNA and subsequently confirmed in genomic DNA. Muscle mRNA was extracted using 30 mg of muscle with the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) and retrotranscribed to cDNA by RT-PCR using polythiamine primers (Invitrogen, Carlsbad, USA). The full DMD transcript was amplified and sequenced in 20 overlapping amplicons with our own primers and others described previously [15]. Sequence analysis was performed by Sanger sequencing method (Big Dye 3.1 chemistry and equipment 3500xL ABI, Applied Biosystems, Foster City, USA).

The impact of the DNA variants detected on mRNA splicing and protein functionality was evaluated by in silico analysis using computational algorithms. Altered splicing sites were analysed using positional weight matrices included in the Human Splicing Finder and Alamut softwares. Pathogenicity of amino acid substitutions was evaluated using Polyphen-2 [16] and SIFT [17] algorithms. All substitutions with a Polyphen-2 score below 1 and a SIFT score below 0.05 were considered damaging substitutions. Moreover, when an aminoacid substitution was detected in any of the 100 healthy controls, pathogenicity was rejected. In addition, we used LOVD database (Leiden Open Variation Database: www.dmd.nl) as a reference to determine if the substitution consisted in a missense mutation or a non-synonymous SNP. The nucleotide position was determined according to the DMD reference sequence (RefSeq NM_004006.2) and mutation nomenclature followed the guidelines of the Human Genome Variation Society (HGVS).

The mutation rate per nucleotide and per generation for each mutation type was calculated according to the formula \( \mu_x = m_{nx} / N_{tx} \), as previously described [18].

MARCOIL program was used to predict the existence and location of potential coiled-coil domains in protein sequences [19].

Results

We identified DMD mutations in 576 unrelated families, 564 of which affected males (360 DMD, 7 IMD and 176 BMD) and 12 affected isolated symptomatic female carriers. We were
unable to assign 21 male patients to a phenotypic category, either because clinical data were lacking or because the patients were too young. Of the 576 independent mutational events, 471 (81.8%) were major rearrangements (exonic deletions and duplications) and 105 (18.2%) were small mutations. The frequency of deletions, duplications and small mutations differed depending on the phenotypic group. BMD patients had more deletions (80%, 141/176) than DMD/IMD patients (66%, 242/367), while the frequency of mutations in BMD patients was lower (9.1%, 16/176) than that in DMD/IMD patients (22.6%, 83/267) (Fig 1, Table 1).

Exonic deletions

We identified 471 (81.8%) intragenic rearrangements, 406 (70.5%) of which were deletions and 64 (11.1%) duplications. In one DMD patient, we detected two apparently independent rearrangements (Del Pb>29 and Dup 37>43; S1 Fig). Both deletions and duplications had a non-random distribution with two hot spots. We found that 73.2% (298/407) of deletions started between introns 43 and 55 (distal hot spot), whereas 18.7% (72/407) started between introns 1 and 20 (proximal hot spot). This shows that deletion breakpoints were mainly concentrated in a few introns at the distal hot spot, while proximal breakpoints were more dispersed (Fig 2). Considering the 814 breakpoints, intron 44 was clearly the most frequently involved in deletions (19.9%, 162/814) and mostly as a 5' breaking point (87.6%), followed by introns 47 (10.3%, 84/814) and 50 (9.1%, 74/814). The proportion of 3' breakpoints respect to 5' breakpoints tended to gradually increase from intron 46 to intron 55. In the proximal region of the gene, introns 7 (4.7%, 38/814) and 2 (2.8%, 23/814) were the most involved. Intron 2 only presented one 5' breakpoint while intron 7 equally presented 5' and 3' breakpoints. The large length of introns 2, 7 and 44 (170 Kb, 110 Kb and 248 Kb, respectively) must be taken into account when considering the frequency of breakpoints.

Deletions affecting only regions outside the two hot spots were unusual: 4.4% (18/407) were located between the two hot spots (introns 21–42), 2% (8/407) starting at 5' end of DMD gene, and 1.7% were located between introns 55 and 79. Only seven cases showed deletions that included the two hot spots (1.7%). Furthermore, 8 deletions started in regions at 5' end of exon 1, deleting brain and muscle promoters. One of them, associated with the DMD phenotype, deleted the entire DMD gene and 5' flanking genes (GK [OMIM: *300474] and OTC [OMIM: *300461]). Three deletions associated with DMD were limited to the promoter region.

In our cohort of mutations, 131 deletions were identified, of which more than half (56.4%, 74/131) were detected only once, in agreement with the high allelic heterogeneity described in the DMD gene. In contrast with findings in a previous paper [20], we observed a greater diversity at the distal hot spot (60 deletions) than at the proximal hot spot (46 deletions). Furthermore, deletions starting at the proximal hot spot had an average larger extension (14 deleted exons) than those starting at the distal hot spot (6 deleted exons). Deletions associated with BMD presented lower heterogeneity since the 10 most frequent deletions accounted for 76%. In contrast, in DMD, 12 recurrent deletions represented 46% of all deletions.

Exonic duplications

Duplications accounted for 11.1% of all identified mutations. Unlike deletions, duplications had a more dispersed distribution and were slightly more frequent in the proximal hot spot (41.5%, 27/65) than in the distal hot spot (32.3%, 21/65) (Fig 2B). Like deletions, duplications presented a great heterogeneity because 36 of the 47 identified duplications were detected only once. Unlike deletions, duplications had more diversity in the proximal hot spot (25 duplications) than in the distal hotspot (13 duplications). Breakpoints were concentrated at the proximal hot spot, in intron 2 (10%, 13/130), intron 7 (7.7%, 10/130), intron 1 (7.7 / 10/130) and
Fig 1. Identified mutations and phenotypic groups.

doi:10.1371/journal.pone.0135189.g001

Table 1. Number of identified mutations.

| Type of mutation        | DMD/IMD | BMD | DMD/BMD | Isolated carrier | Total | %     |
|-------------------------|---------|-----|---------|------------------|-------|-------|
| Exonic deletion         | 242     | 141 | 18      | 5                | 406   | 70.5% |
| In-frame                | 18      | 127 | 15      |                  | 158   |        |
| Frameshift              | 220     | 14  | 3       | 5                | 244   |        |
| Others                  | 4       |     |         |                  | 4     |        |
| Exonic duplication      | 41      | 19  | 3       | 1                | 64    | 11.1% |
| In-frame                | 7       | 12  | 2       | 1                | 22    |        |
| Frameshift              | 34      | 7   | 1       |                  | 42    |        |
| Others                  | 0       |     |         |                  | 0     |        |
| Complex rearrangements  | 1       |     |         |                  | 1     | 0.2%  |
| Nonsense                | 46      | 5   | 3       |                  | 54    | 9.4%  |
| UGA                     | 19      | 3   |         |                  | 22    |        |
| UAG                     | 15      | 1   |         |                  | 17    |        |
| UAA                     | 12      | 1   |         |                  | 15    |        |
| Indels                  | 21      | 3   | 2       |                  | 26    |        |
| Frameshift insertion    | 6       | 1   |         |                  | 7     |        |
| Frameshift deletion     | 11      | 2   | 1       |                  | 14    |        |
| Frameshift indel        | 3       |     | 1       |                  | 4     |        |
| In-frame deletion       | 1       |     |         |                  | 1     |        |
| Missense                | 3       | 1   |         |                  | 4     | 0.7%  |
| Splice Site             | 13      | 6   | 1       |                  | 20    | 3.5%  |
| Pseudoxon               | 1       |     |         |                  | 1     | 0.2%  |
| Total Mutations         | 367     | 176 | 21      | 12               | 576   | 100%  |

doi:10.1371/journal.pone.0135189.t001
intron 9 (4.6%, 6/130). Distal breakpoints in duplications were less frequent than in deletions. Intron 7 presented similar breakpoints frequency between deletions and duplications with analogous proportions for 5’ and 3’ breakpoints.

No significant difference was observed in the size of the duplication between the proximal and distal hot spots. The most frequent duplication was that of exon 2, 7.7% (5/65), and it was associated with DMD in all cases. Duplications of exons 3–7, 5, 8–9, 50 and 56–62 were identified three times (4.6% all).

Fig 2. Distribution of intronic breakpoints in large intragenic rearrangements in the DMD gene. (A) Breakpoints in deletions. (B) Breakpoints in duplications. 5’ breakpoints in grey and 3’ breakpoints in white.

doi:10.1371/journal.pone.0135189.g002
Small mutations

We identified 98 mutations in 105 unrelated individuals (18.2%, 105/576), 55 of which have not been previously identified in the LOVD database. We identified a variety of mutations: 54 nonsense mutations, 15 microdeletions, 11 insertions/duplications, 20 splice site mutations, 4 missense, and one deep intronic mutation. The frequency of mutation types differed according to the clinical phenotype (Fig 3). The vast majority of DMD patients presented frameshift or nonsense mutations, causing a premature stop codon and a truncated protein rapidly degraded by the NMDA process. (81%). Nonsense substitutions are the most common type in patients with DMD/IMD (56.1%). However, most mutations in BMD patients affected mRNA splicing process (43.8%), while nonsense and frameshift mutations accounted for 31.25% and 18.75%, respectively. No recurrent mutations or hot spots were identified because they are distributed throughout all DMD exons involving all dystrophin domains (Figs 4 and 5). Table 2 specifies the rate and mutational target size for each type of small mutation. Single base substitutions were 2.4 times more frequent than small deletions or insertions, presenting a 15.4 times higher rate. The mutational rates per nucleotide 6.02x10-9 (all single nucleotide substitutions) and 0.39x10-9 (insertions/deletions small) were slightly lower than those published in a previous study [18].

Nonsense mutations

Nonsense mutations represented 51.4% (54/105) of the small mutations and 9.4% (54/576) of the total mutations. The UGA stop codon was the most frequent (42.6%), followed by UAG (29.6%) and UAA (27.8%). The DMD gene (Dp427m muscle isoform) has a total of 1,500 triplets that can be mutated into stop codon by a substitution of a single nucleotide. Transitions (77.8%) were more frequent than transversions (22.2%), and the C>T transition was the most common (90.5%).

Frameshift mutations

Frameshift mutations were identified in 23.8% (25/105) of patients with small mutations. They were caused by deletion, insertion or deletion-insertion events (generally involving 1–5 nucleotides). Only two exceptions were observed: a deletion of 35 bp in exon 45 and an insertion of 18 bp in exon 11.

Most identified mutations in our cohort have not been previously described. Only two positions were recurrent although the mutations located therein were not identical: c.6127del and c.6128_6131del in exon 43 and c.10231_10235del and c.10235del in exon 71.

Splicing mutations

Twenty splice site mutations were identified in 21 unrelated patients, representing 20% (21/105) of small mutations and 3.6% (21/576) of total mutations. Most of these changes were located in the canonical dinucleotides AG/GT of natural splice sites (65%, 13/20); while mutations located in less conserved positions were rare (Fig 6). Mutations affecting donor sites (5’ ss) were slightly more frequent (52.4%, 11/21) than those affecting acceptor sites (3’ ss) (38.1% 21/08). Two mutations were located outside natural splice sites. The deep intronic mutation C.9225-647A located in intron 62 was detected through muscular cDNA analysis. This mutation activated a cryptic donor site that, along with a cryptic acceptor, caused the inclusion of a 67 bp pseudoexon at the mature mRNA level. The second mutation was an apparent missense mutation at exon 38, c.5444A>G/ p.Asp1815Gly. The cDNA analysis showed that the mutation caused a 5 bp deletion due to the creation of a new donor site. The splicing pattern of 14
splice site mutations was determined. In most cases (78.6%, 11/14) splicing mutations caused complex patterns with levels of more than one transcript [19].

Missense and in-frame mutations

Only four missense mutations and one in-frame deletion of a single amino acid (4.8% of point mutations and 0.9% of total mutations) were identified. Four of these mutations were associated with DMD and IMD phenotypes, while only one was associated with an atypical BMD patient. Two of the four were located at the N-terminal actin binding domain (ABD1): p.Leu53Arg in a DMD patient with irregular dystrophin reduction and p.Gly166Val in an IMD patient.

**Fig 3. Distribution of identified point mutations and phenotypic groups.**

doi:10.1371/journal.pone.0135189.g003

**Fig 4. Distribution of point mutations distribution along the dystrophin domains.** Mutations detected in female isolated carriers in black. CH1-2: calponin homology domains binding actine ABD1; H1–H4: hinge regions; R1-24: spectrin-like repeats; WW: domain containing two tryptophans; EF-1-2: putative calcium binding sites; ZZ: zinc-finger domain.

doi:10.1371/journal.pone.0135189.g004
patient without muscle biopsy. A double aminoacid change, p.Met450Ile_Asp451Tyr, located at R2 of central rod domain, was identified in an IMD patient with irregular dystrophin reduction. Two mutations were identified in the distal domains. The p.Pro3320Ser mutation, located in ZZ domain (zinc-finger) of the cystein rich region (CRD), was identified in a BMD patient with near normal dystrophin levels. This patient presented an atypical phenotype with microphthalmia in the right eye, vitreous hyperplasia and severe cognitive delay. The deletion p. Glu3367del located in the C-terminal domain was identified in a DMD patient without immuno-histochemistry data.

The small mutations identified in this work will be submitted to LOVD database.

Discussion

This is the third largest series of dystrophinopathy patients described to date, with 576 unrelated patients [18, 20, 21]. The results illustrate the high allelic heterogeneity of the DMD gene.

Table 2. Mutation rate per nuclotide and type of mutation. Mutational type target was calculated in nucleotides according to muscular isoform Dp427m (NM_004006). $\mu_x$ is the mutational rate per nuclotide and per generation for each mutation type.

| Mutation type          | Number of mutations | Target (nt) | $\mu_x$ mutational rate ($x10^{-9}$) |
|------------------------|---------------------|-------------|-------------------------------------|
| One base substitution  | 66                  | 1812        | 6.02                                |
| Substitution at splice sites | 12              | 312         | 6.36                                |
| Nonsense substitution  | 54                  | 1500        | 5.95                                |
| Transition at CpG sites | 20                | 29          | 114.03                              |
| Transversion at CpG sites | 0                | 7           | 0.00                                |
| Transition at not CpG sites | 22              | 380         | 9.57                                |
| Transversion at not CpG sites | 12              | 1091        | 1.82                                |
| Small indels           | 27                  | 11370       | 0.39                                |
| Indels at CDS          | 26                  | 11058       | 0.39                                |
| Indels at splice sites  | 1                   | 312         | 0.53                                |

doi:10.1371/journal.pone.0135189.t002

doi:10.1371/journal.pone.0135189.g005
We identified 276 different mutations, 85 of which have not been previously described. One hundred and thirty-one were exonic deletions, 46 were exonic duplications, one was a complex rearrangement deletion/duplication, and 98 were small mutations.

The diagnostic algorithm used consisted of the analysis of the exonic copy number, followed by the analysis of small mutations by sequencing genomic DNA or cDNA from muscle biopsy when available, for negative exonic deletions/duplications. Our results confirm that it is an accurate algorithm for the molecular diagnosis of dystrophinopathies. Despite the study of muscle cDNA requires an invasive method as muscle biopsy, it allows: 1) detection of all types of mutations, including deep intronic mutations, 2) assessment of the impact of DNA variants on pre-mRNA splicing to identify splice sites (ss) abnormalities or regulatory elements (SRE), and 3) evaluation of the reading frame conservation that determines the phenotypic severity. An example is the mutation c.5444A>G, which could have been classified as a non-pathogenic missense change (p.Asp1815Gly) when in fact it caused aberrant splicing, generating a frameshift transcript. However, care must be taken in the study of point mutations in mRNA; some splicing mutations in BMD patients can induce significant levels of normal transcripts, making it difficult to detect aberrant mRNA variants. This is the case of the mutation c.3603 + 2dupT in which the anomalous transcript only represented 17% of total transcripts.

The frequency for each mutation type was similar to that described previously [22] and differed between DMD and BMD phenotypes (Figs 1 and 3). BMD patients had fewer point mutations and more exonic deletions than DMD patients. These differences were more pronounced in the point mutations. In DMD patients, we found most point mutations were frameshift or nonsense type, according to the reading frame. However, our BMD patients had a high frequency of splicing mutations, although they presented many exceptions to the reading frame law, as up to 50% of mutations were frameshift or nonsense type.

In accordance with previous studies [18, 20, 23, 24], we noted that large deletions and duplications had a non-random distribution with the presence of two hot spots. In our cohort, as in
a previous study [25], the intronic size was not the only factor determining deletional profiles. Several mechanisms involved in the development of genomic rearrangements have been reported [26–28]. The non-allelic homologous recombination (NAHR, non-allelic homologous recombination) is a mechanism described in numerous genetic disorders that can cause deletions and duplications in the same frequency [29–31]. The Alu repeats crosslinking by the NAHR mechanism have been considered a cause of deletions in several genes, including the DMD gene [32]. Analysis of breakpoints in the DMD gene shows that exonic deletions and duplications present different frequencies, caused by different mechanisms. If both, deletions and duplications were the result of NAHR, we would expect similar deletion and duplication frequencies for each intron. It has also been suggested that duplications could arise at different times in the cellular cycle. Like point mutations, the deletions are predominantly maternally inherited, while duplications descend from the paternal germ line [26,33,34]. It has been reported that the duplication of exon 2 is caused by the non-homologous end joining mechanism (NHEJ) involved in the double strand DNA break repair [24].

Unlike deletions/duplications, point mutations have no hot spots and are distributed along the entire gene (Fig 4). The only exceptions are missense mutations that mainly concentrate in the N- and C-terminal ends of binding protein domains, in agreement with previous publications [20]. Half of the identified mutations in our study were not previously described, confirming the necessity to study the whole gene in molecular diagnosis.

Genotype/phenotype correlation

The phenotypic severity depends mainly on the reading frame rule [4]. This rule postulates that mutations destroying the reading frame cause absence of dystrophin in skeletal muscle and the DMD phenotype, whereas mutations preserving the reading frame permit the expression of semifunctional dystrophin and BMD phenotype. The workflow (MLPA, sequencing, in silico analysis and mRNA analysis) used in this study has allowed us to better find exceptions to the reading frame rule and to better understand the genotype-phenotype correlation. In our cohort, the reading frame rule was fulfilled in 90.4% of DMD patients and in 82.4% of BMD patients. Exonic deletions were the mutational group that had fewest exceptions to the rule (8.4%, 32/379), while exonic duplications and point mutations presented exceptions in similar proportions, 23.3% (14/60) and 19.2% (19/99) respectively.

Several mechanisms explaining the exceptions to the reading frame law have been described. It is assumed that duplications occur in tandem, without having an mRNA study to support this in most cases. It seems certain that most are tandem duplications [35] because noncontiguous rearrangements cases have been described causing complex effects at the mRNA level [24]. Furthermore, it is unknown how large in-frame duplications can affect the dystrophin function. Regarding deletions several considerations can be made. In DMD patients, 44% (8/18) of the identified exceptions were deletions causing partial or total loss of a binding protein domain that would compromise the protein function. In 7 patients, the mutation affected the ABD domain and in one patient it affected the CRD region (Fig 7). Deletions affecting the brain and muscle promoters were associated in all cases with the DMD phenotype. According to previous descriptions, the two frameshift deletions at the 5’ end (3>6 and 3>7) accounted for 36% of the exceptions associated with BMD. Several mechanisms seem to be involved in the rescue of dystrophin expression in frameshift mutations located at the 5’ end. These mechanisms include alternative translation initiation in exon 6 or 8 [36,37] and patterns of alternative splicing [38].

Small mutations also present numerous exceptions to the reading frame rule, especially in BMD patients, in whom most exceptions are due to alterations in the normal splicing pattern
All nonsense or frameshift mutations associated with BMD are located in in-frame exons (exons 9, 28, 37, 71, and 74). In these mutations, the alteration of splicing regulatory elements (SRE) can increase the levels of transcripts with in-frame skipping, leading to the rescue of the phenotype [40]. In severe DMD or IMD patients, all exceptions are missense mutations located in critical domains for protein function. Previous publications [18] assumed that mutations in natural splice sites always cause exon-skipping. mRNA analysis shows that these mutations...
often cause complex splicing patterns which may include skipping of one or more exons, activation of cryptic splice sites and intronic retention.

Concerning altered splicing patterns, two types of Alu retrotransposon insertions have been described in the DMD gene: one in an XLCM patient, and the other in a DMD patient [41,42]. In both cases, the insertion of the Alu element occurred inside the intron, modifying the splicing pattern. This altered pattern caused the skipping of a closer exon in one case and the insertion of the Alu element in the mature mRNA in the other case. Patient #1990 presented an insertion of 18 bp in exon 11. This inserted fragment showed a high sequence homology with part of the retrotransposon elements of the Alu J family. In our patient, we were unable to determine whether the insertion altered the splicing because no muscle biopsy was available for mRNA analysis.

**Protein domains changes: missense and in-frame mutations**

Missense mutations are exceptions to the reading frame rule and often cause an unusual combination of severe phenotypes with dystrophin expression. According to previous publications [18, 20], missense mutations are rare (0.9%) and most are located in protein-protein interaction domains. However, missense DMD mutations have proven to be valuable in the analysis of pathological dystrophin alterations.

In our cohort, we identified two mutations in the N-terminal F-actin binding domain (ABD1). This domain is composed of two calponin homologous (CH1-2) modules with three actin-binding regions (ABS1-3). The domain ABD1, along with an additional domain located at the rod domain (ABD2), allows dystrophin to combine with actin filaments, forming bundles and networks and avoiding the depolymerization of filaments [43] (Fig 4). It has been reported that missense mutations in the ABD1 domain decrease the thermodynamic stability of dystrophin, causing misfolding and aggregation into amyloid-like structures [44]. We identified the mutation p.Leu53Arg in the CH1 module in a DMD patient, whereas the mutation p.Gly166Val in the CH2 module was identified in an IMD patient. The difference in clinical severity between the two mutations suggests they affect the structure of ABD1 domain and its ability to interact with actin differently. The domain ABD1 was the first protein domain in which the crystal structure was determined (S2A Fig) [45]. The p.Leu53Arg mutation in CH1 introduces a charged residue on a hydrophobic region that is structurally closer to the actin binding sites (ABS1-3) (S2B Fig). Hypothetically, the mutation could compromise the binding with actin and cause a DMD phenotype even without altering the dystrophin expression. According to this hypothesis, a mutation in the adjacent residue (p.Leu54Arg) has been described in a DMD patient [46]. However, the mutation in CH2 (p.Gly166Val) is not structurally located close to ABS3, indicating it does not interact with actin. This mutation replaces a small neutral residue with a hydrophobic residue at the beginning of an alpha helix where mutations associated with BMD have been described (Asp165, Ala168 and Ala171) [47]. This suggests that this region is critical for CH2 stability (S2C Fig). Our data concerning the location of the mutated residue in relation to phenotype correlate with functional studies by Henderson and co-workers [48]. These authors suggested that missense mutations located in CH1 are associated with severe phenotype due to the combined effect of alterations in actin binding and induction of thermodynamic instability. They observed that p.Leu54Arg decreases the actin binding affinity four-fold and induces aggregation and thermal denaturation. In contrast, p.Asp165Val, p.Ala168Asp and other mutations located in CH2, associated with BMD, increase protein aggregation and denaturation without altering the actin binding affinity [48].

In our cohort, a mutation consisting in two amino acid substitutions in the central rod domain (p.Met450Ile_Asp451Tyr) was identified in IMD patient #1215. To our knowledge,
several missense mutations have been described in this domain in the literature [49,50] and in LOVD. The rod domain consists of 24 repeats similar to spectrin (R1–R24) and 4 hinge regions (H1–H4) [51] (Fig 4). It is believed that the dystrophin acts by protecting the membrane from damage caused by muscle contraction. Spectrin-like repeats participate in this biomechanical function, acting as springy units that can be deployed when they are subjected to strength [52]. Initially, it was thought that the spectrin-like repeats had a very low importance in the overall function of dystrophin, since in-frame deletions removing large portions of the rod domain were observed in mild phenotypes [53]. However, several studies suggest that the rod domain has a more complex role than a purely mechanical function. The study of therapeutic mini-dystrophin in mdx mice revealed that 3 or more repeats are required to retain the protein functionality [54, 55]. Moreover, several repeats interact with ligands such as F-actin, sinemin, Par-1, nNOS and phospholipids [56–60].

Although the repeats of the spectrin protein family (spectrin, dystrophin, utrophin, α-actinin, etc) exhibit a relatively low homology they present a heptade periodic pattern that is characteristic of coiled-coil structures (S3A Fig). This pattern consists of seven hydrophobic and hydrophilic residues represented by the letters a to g. The “a” and “d” residues are mostly hydrophobic and ensure the antiparallel folding of three alpha helices (HA, HB and HC) forming a supercoiled bundle or coiled-coil [61]. The other positions are usually occupied by hydrophilic or charged residues, so that the helix is coiled between them, hiding the hydrophobic residues inside the bundle and exposing the hydrophilic/charged residues outside the bundle (S3B Fig). It is believed that dystrophin adjacent repeats are joined by a connector that ensures the helicoidal continuity of the last helix in the first repeat (HC) with the first helix in the next repeat (HA) [62]. The double change p.Met450Ile_Asp451Tyr identified in IMD patient #1215 is located at the beginning of the HA helix of the R2 repeat (S3C Fig). Dystrophin immunostaining shows dystrophin and presence of negative fibers since the change induces instability or folding defects leading to dystrophin degradation. According to this hypothesis, the alignment of repeats indicates that the mutated residues are located in heptad positions “a” (Met450) and “b” (Aps451), suggesting that the mutation alters the coiled coil structure of R2 repeat (S3A Fig).

Several algorithms have been described to predict coiled coil domains. One of these algorithms, MARCOIL, establishes the tendency to form coiled coils in a certain heptade position for each residue [63]. The MARCOIL analysis of the wild-type dystrophin and p.Met450Ile_Asp451Tyr dystrophin shows that the mutation causes a dramatic change in the probability of forming coiled coils of 434–477 residues, corresponding to HC helix of R1 and HA helix of R2 (S3D Fig). These data suggest that the mutation changes the protein microenvironment of R1–R2 leading to misfolding and/or thermodynamic instability of the protein. Recently it has been described the presence of p.Leu427Pro mutation in R1 repeat in two brothers with mild BMD phenotype. The patients have a weak immunostaining in N-terminal region of dystrophin (ABD1 and H1) and the mutation would originate a partial misfolding. These authors suggested that the mutation affects the dynamic properties of the entire N-terminal region [49]. Moreover, it has been described that the combination of two polymorphic variants (p. Glu2910Val and p.Asn2912Asp) in the R23 repeat causes DMD due to the destabilization of repeat [50]. These changes, along with the mutation identified in our patient, correlate with mini-dystrophin studies [54] and a BMD patient who presented minimal muscle involvement and in-frame deletion of exons 14 to 48 (R3–R19) [53]. These data suggest that regions R1-3 and R20-24 are essential for the proper function of dystrophin. Some authors have hypothesized that these regions contribute to the stabilization of the adjacent N- and C-terminus domains involved in protein-protein interactions [49,50].
In the cysteine-rich region, the mutation p.Pro3320Ser at ZZ domain (zinc-finger domain) (Fig 4) was identified in a patient with atypical BMD phenotype. This patient, #1497, presented mild muscle weakness, microphthalmia, vitreous hyperplasia, severe cognitive delay and, interestingly, almost normal dystrophin expression in skeletal muscle. ZZ domains are small protein motifs that have up to four conserved cysteines allowing zinc binding or other metals (S4A and S4B Fig)[64]. The zinc binding induces conformational changes permitting binding to specific ligands, such as DNA or other proteins [65]. The cysteine rich region of dystrophin (CRD) has been implicated in binding to β-dystroglycan [66–68]. The CRD region comprises several modular domains: a WW domain, two putative calcium binding sites (EF-hand 1 and 2) and one ZZ domain. The WW domain contains two conserved tryptophans (W) that allows the binding of dystrophin with the last 15 C-terminal residues of β-dystroglycan (S4C Fig).

Some studies demonstrate that WW domain is not sufficient by itself to establish the union with β-dystroglycan and requires the presence of both EF and ZZ domains for a stable interaction [69–71]. In 2007, Hnia and co-workers identified two zinc-binding regions and one point interacting to β-dystroglycan in the ZZ domain (S4B Fig) [70]. The p.Pro3320Ser mutation, identified in patient #1497, is located in the first zinc-binding region, adjacent to the Cys3319 residue (S4B Fig). This location suggests that the change alters the ability to bind zinc in the first region and consequently alters the conformation of the ZZ domain involving the interaction with β-dystroglycan. The BMD phenotype indicates that the mutation does not completely destroy interaction with β-dystroglycan, as expected by a severe DMD phenotype. We observed that mutations located in the first zinc-binding region are mainly associated with the BMD phenotype, whereas those located in the second zinc-binding region, which includes the anchor point to β-dystroglycan, are associated with the DMD phenotype (S4B Fig). The patient’s severe mental retardation correlates with the location of the mutation in the C-terminal end of the gene, affecting all DMD isoforms including Dp71. Dp71 is the most abundant form in fetal and adult brain [72] and has been described as the main factor determining the severity of cognitive impairment. Mutations in Dp71 are associated with severe mental retardation [73, 74].

The atypical clinical presentation of the patient, microphthalmia and vitreous hyperplasia which are not associated with dystrophinopathy, encompass some forms of congenital muscular dystrophy caused by glycosylation defects of α-dystroglycan. The fact that the mutation alters the interaction with β-dystroglycan questions whether the structural changes are caused by dystrophinopathy or whether there are two separate pathologies.

In the C-terminal domain, we identified a deletion of a single amino acid (p.Glu3367del) associated with the DMD phenotype. The mutation is located 13 residues from the ZZ domain in a region with unknown function, although it is one of the most conserved dystrophin regions. This mutation has been previously described in two IMD and one DMD patients. Becker and co-workers suggested that the deletion of the Glu3367 residue causes a torque and/or translation of an α-helix that may induce alterations in the conformation or function of the ZZ domain [75].

**Variability of DMD gene**

X-linked diseases provide data on the human genome mutation rate [76,77]. Direct and indirect measures suggest that the genomic mutation rate is 1-2x10⁻⁸ per nucleotide. The rate per nucleotide mutation observed in our sample was 0.6x10⁻⁸, slightly lower than described to date. This could be due to enrichment with large rearrangements respect to point mutations in our sample. According to spontaneous deamination of methylated cytosines [78], CpG transitions in the CGA codon (arginine) represent 37% of total nonsense identified mutations although this codon represents only 2% of the target codons. The 11.9-fold difference in the number of
CpG transitions compared to non-CpG transitions is similar to that obtained by measuring the divergence between humans and chimpanzees, observed to be 10 times higher for CpG sites [79]. According to previous publications [39], there are no hot spots for small insertions/deletions, although the study of the mutated sequence reveals that in most cases the presence of repeated motifs is implicated in the etiology of such mutations.

The sequencing of the coding and flanking intron regions allowed us to identify 119 SNPs (S1 and S2 Tables), 21 of which had not been previously described in LOVD database, dbSNP and HapMap. The study of haplotypes obtained by sequencing reveals the variability in the DMD gene. Just as the point mutations study reveals that 56% are private mutations, study of the SNPs shows that the vast majority of unrelated families present a unique haplotype for DMD locus. This probably reflects the high rate of DMD recombination linked to its large size. Of the 119 identified SNPs, 93 are located in intron regions and 26 in coding exons. Of these 26, 11 were synonymous and 15 were non-synonymous changes, involving the substitution of one amino acid for another. Two non-synonymous SNPs, p.Lys1491Thr and p.Met1483Val, have not been described previously. Both are located in exon 32, corresponding to the R11 repeat of rod domain. However, we can not affirm whether they are rare variants or whether they have a pathogenic effect.

Conclusions
The diagnostic algorithm described in this work was accurate for the molecular diagnosis of dystrophinopathies. It analyzed the exonic copy number and point mutations by sequencing cDNA from muscle biopsy or genomic DNA for negative deletions/duplications. There were no hot spots for small insertions/deletions. The study of the mutated sequences showed that repeated motifs were implied in the etiology in most cases. A detailed analysis of missense mutations contributed significantly to understanding their impact on the protein structure and to explain the non-fulfilment of the reading frame law regarding genotype/phenotype correlation.

Supporting Information
S1 Fig. Complex rearrangement in #1612 DMD patient: del Pb > 29 and dup 37 > 43. (A) MLPA results. (B) Diagram of DMD mutated gene in this patient.
(TIF)

S2 Fig. Missense mutations in N-terminal acting binding domain (N-ABD1). (A) Tridimensional structure of N-ABD domain with calponin-like domains (CH 1–2). ABS1: residues from 17 to 26; ABS2: residues from 102–114; ABS3: residues from 130–146. (B) Module CH1 with the Leu54 residue that reduces four times the actin binding affinity, (C) Module CH2: mutations associated to BMD phenotype leading to thermodynamic instability and not altering actin binding.
(TIF)

S3 Fig. Double missense mutation at R2 in rod domain and its impact on dystrophin. a. R1 and R2 tridimensional structure: mutated residues and the three helix HA,HB and HC show antiparallel coiled-coil formation. b. HA alienation with seven spectin-like repeats from other proteins. Residues with sequence homology are coloured. Heptade pattern with hydrophobic residues at “a” and “d” positions. c. Diagram showing a trimeric coiled-coil: hydrophobic residues at the nucleus and hydrophilic.loaded residues outside. d. MARCOIL result for coiled coils in residues 420–527: wild type protein (in blue) and mutated p.Met450Ile_Asp451Tyr protein (in red).
(TIF)
S4 Fig. Missense mutation at ZZ domain. (A) Murine CBP ZZ domain residues coordinating zinc binding in yellow. (B) Diagram of dystrophin and β-dystroglican binding. (C) Dystrophin ZZ domain diagram showing the two zinc-binding regions. Zn-co-ordinating residues In yellow; Pro3320 mutated residue in red and the second interaction point site with β-dystroglican in orange. Arrows indicate missense mutations described in LOVD database: DMD patients in black and BMD patients in blue. (TIF)

S1 Table. SNPs in coding region. *Asterisks indicate previously nondescribed changes with unknown pathogenic effect. (DOC)

S2 Table. SNPs in non-coding regions. *Asterisks indicate previously nondescribed changes with unknown pathogenic effect. (DOC)

Acknowledgments
The authors thank all patients and their family members for their participation in this study. We thank Carolyn Newey for her kind language assistance and Laura Alías for the images editing support. The study is sponsored through a governmental grant of the Instituto de Salud Carlos III (PI 11/02586) which is co-funded by FEDER.

Author Contributions
Conceived and designed the experiments: JJM LGQ PG. Performed the experiments: JJM MJR MB EV LGQ. Analyzed the data: JJM LGQ PG. Wrote the paper: JJM LGQ PG. Clinical Characterization: AN CO. Intellectual Discussion Support: MBB.

References
1. Hoffmann EP, Brown RH Jr, Kunkel LM. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 1987; 51 (6): 919–928. PMID:3319190
2. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988; 53 (2): 219–228. PMID:3282674
3. Ervasti JM. Costameres: The Achilles’ heel of herculean muscle. J Biol Chem 2003; 278 (16): 13591–13594. PMID:12556452
4. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2 (1): 90–95. PMID:3384440
5. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2 (12): 731–740. PMID:14636778
6. Miller LA, Romitti PA, Cunniff C, Druschel C, Mathews KD, Meaney FJ, et al. The muscular dystrophy surveillance tracking and research network (MD STARnet): Surveillance methodology. Birth Defects Res A Clin Mol Teratol 2006; 76 (11): 793–797. PMID:17036307
7. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990; 86 (1): 45–48. PMID:2253937
8. White S, Kall M, Liu Q, Villerius M, Engelsma D, Kriek M, et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 2002; 71 (2): 365–374. PMID:12111668
9. Schwartz M, Duno M. Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genet Test 2004; 8 (4): 361–367. PMID:15684864
10. Mendell JR, Buzin CH, Feng J, Yan J, Serrano C, Sangani DS, et al. Diagnosis of duchenne dystrophy by enhanced detection of small mutations. Neurology 2001; 57 (4): 645–650. PMID:11524473
11. Bennett RR, den Dunnen J, O’Brien KF, Darras BT, Kunkel LM. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet 2001; 2: 17. PMID: 11710958

12. Dolinsky LC. Denaturing gradient gel electrophoresis (DGGE) for mutation detection in duchenne muscular dystrophy (DMD). Methods Mol Biol 2003; 217: 165–175. PMID: 12491931

13. Hofstra RM, Mulder IM, Vossen R, de Koning-Gans PA, Kraak M, Ginjaar IB, et al. DGGE-based whole-gene mutation scanning of the dystrophin gene in duchenne and becker muscular dystrophy patients. Hum Mutat 2004; 23 (1): 57–66. PMID: 14695533

14. Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003; 72 (4): 931–939. PMID: 12632325

15. Deburgrave N, Daoud F, Llense S, Barbot JC, Récan D, Peccate C, et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007; 28 (2): 183–195. PMID: 17041906

16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7 (4): 248–249. doi:10.1038/nmeth0410-248 PMID: 20354512

17. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4 (7): 1073–1081. doi:10.1038/nprot.2009.86 PMID: 19561590

18. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, et al. Mutation spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort. Hum Mutat 2009; 30 (12): 1657–1666. doi:10.1002/humu.21114 PMID: 19937601

19. Delorenzi M, Speed T. An HMM model for coiled-coil domains and a comparison with PSSM-based predictions. Bioinformatics 2002; 18(4): 617–625 PMID: 12016059

20. Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype correlations in DMD/BMD patients: A model of nationwide knowledgebase. Hum Mutat 2009; 30 (6): 934–945. doi:10.1002/humu.20976 PMID: 19367636

21. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The Treat NMD Global Database: Analysis of more than 7000 Duchenne Muscular Dystrophy mutations. Human Mutation 2015; 36: 395–402 doi: 10.1002/humu.22758 PMID: 25604253

22. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one japanese referral center. J Hum Genet 2010; 55 (9): 379–388.

23. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the leiden duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34 (2): 135–144. PMID: 16770791

24. White SJ, den Dunnen JT. Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res 2006; 115 (3–4): 240–246. PMID: 17124406

25. Zhong M, Pan SY, Lu BX, Jiang L, Li W. Cloning and sequencing of the junction fragment of dystrophin gene with exons 3 to 5 deletion. Nan Fang Yi Ke Da Xue Xue Bao 2006; 26 (6): 757–759. PMID: 16793593

26. Hu XY, Ray PN, Murphy EG, Thompson MW, Worton RG. Duplicational mutation at the duchenne muscular dystrophy locus: Its frequency, distribution, origin, and phenotype genotype correlation. Am J Hum Genet 1990; 46 (4): 682–695. PMID: 2316519

27. Shaffer LG, Lupski JR. Molecular mechanisms for constitutional chromosomal rearrangements in humans. Annu Rev Genet 2000; 34: 297–329. PMID: 11092830

28. Heldeday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 2003; 532 (1–2): 103–115. PMID: 14643432

29. Ji Y, Eichler EE, Schwartz S, Nicholls RD. Structure of chromosomal duplicons and their role in mediating human genomic disorders. Genome Res 2000; 10 (5): 597–610. PMID: 10810082

30. Emanuel BS, Shaikh TH. Segmental duplications: An 'expanding' role in genomic instability and disease. Nat Rev Genet 2001; 2 (10): 791–800. PMID: 11584295

31. Stankiewicz P, Lupski JR. Molecular-evolutionary mechanisms for genomic disorders. Curr Opin Genet Dev 2002; 12 (3): 312–319. PMID: 12076675

32. Deininger PL, Batzer MA. Alu repeats and human disease. Mol Genet Metab 1999; 67 (3): 183–193. PMID: 10381326
33. Grimm T, Meng G, Liechti-Gallati S, Bettecken T, Muller CR, Muller B. On the origin of deletions and point mutations in duchenne muscular dystrophy: Most deletions arise in oogenesis and most point mutations result from events in spermatogenesis. J Med Genet 1994; 31 (3): 183–186. PMID: 8014964

34. Tuffery-Giraud S, Saquet C, Chambert S, Echenne B, Marie Cuisset J, Rivier F, et al. The role of muscle biopsy in analysis of the dystrophin gene in duchenne muscular dystrophy: Experience of a national referral centre. Neuromuscul Disord 2004; 14 (10): 650–658. PMID: 15351422

35. Hu XY, Ray PN, Worton RG. Mechanisms of tandem duplication in the duchenne muscular dystrophy gene include both homologous and nonhomologous intrachromosomal recombination. EMBO J 1991; 10 (9): 2471–2477. PMID: 1688831

36. Winnard AV, Mendell JR, Prior TW, Florence J, Burghes AH. Frameshift deletions of exons 3–7 and revertant fibers in duchenne muscular dystrophy: Mechanisms of dystrophin production. Am J Hum Genet 1995; 56 (1): 158–166. PMID: 7825572

37. Gurvich OL, Maiti B, Weiss RB, Aggarwal G, Howard MT, Flanigan KM. DMD exon 1 truncating point mutations: Amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat 2009; 30 (4): 633–640. doi: 10.1002/humu.20913 PMID: 19206170

38. Gualandi F, Rimessi P, Trabaneli C, Spitali P, Neri M, Patamello T, et al. Intrinsic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5’ mutation hot spot of the dystrophin gene. Gene 2006; 370: 26–33. PMID: 16439068

39. Juan-Mateu J, González-Quereda L, Rodríguez MJ, Verdura E, Lázaro K, Jou C, et al. Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes. PLoS One 2013 8 (3):e59916

40. Juan-Mateu J, Paradas C, Olive M, Verdura E, Rivas E, González-Quereda L, et al. Isolated cardiomyopathy caused by a DMD nonsense mutation in somatic mosaicism: Genetic normalization in skeletal muscle. Clin Genet 2012; 82 (6): 574–578. doi: 10.1111/j.1399-0004.2011.01814.x PMID: 22092019

41. Ferlini A, Galie N, Merlino L, Sewry C, Branzi A, Muntoni F. A novel alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet 1998; 63 (2): 436–446. PMID: 9683584

42. Sediackova J, Vondracek P, Hermanova M, Zamecnik J, Hruba Z, Haberlova J, et al. Point mutations in czech DMD/BMD patients and their phenotypic outcome. Neuromuscul Disord 2009; 19 (11): 749–753. doi: 10.1016/j.nmd.2009.08.011 PMID: 19783145

43. Rybakova IN, Humston JL, Sonnemann KJ, Ervasti JM. Dystrophin and utrophin bind actin through distinct modes of contact. J Biol Chem 2006; 281 (15): 9996–10001. PMID: 16478721

44. Singh SM, Kongari N, Cabello-Villegas J, Mallela KM. Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates. Proc Natl Acad Sci U S A 2010; 107 (34): 15069–15074. doi: 10.1073/pnas.1008818107 PMID: 20696926

45. Norwood FL, Sutherland-Smith AJ, Keep NH, Kendrick-Jones J. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause duchenne or becker muscular dystrophy. Structure 2000; 8 (5): 481–491. PMID: 10801490

46. Prior TW, Papp AC, Snyder PJ, Burghes AH, Bartolo C, Sedra MS, et al. A missense mutation in the dystrophin gene in a duchenne muscular dystrophy patient. Nat Genet 1993; 4 (4): 357–360. PMID: 8401582

47. Hamed SA, Hoffman EP. Automated sequence screening of the entire dystrophin cDNA in duchenne dystrophy: Point mutation detection. Am J Med Genet B Neuropsychiatr Genet 2006; 141B (1): 44–50. PMID: 16331671

48. Henderson DM, Lee A, Ervasti JM. Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation. Proc Natl Acad Sci U S A 2010; 107 (21): 9632–9637. doi: 10.1073/pnas.1001517107 PMID: 20457930

49. Acasci G, Moore SA, Cheron A, Delalonde O, Bennett L, Kupsky W, et al. Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild becker muscular dystrophy. J Biol Chem 2012; 287 (22): 18153–18162. doi: 10.1074/jbc.M111.284521 PMID: 22453924

50. Legardini S, Legrand B, Raguenaus-Nicol C, Bondon A, Hardy S, Tascon C, et al. A two-aminoc acid mutation encountered in duchenne muscular dystrophy decreases stability of the rod domain 23 (R23) spectrin-like repeat of dystrophin. J Biol Chem 2009; 284 (13): 8822–8832. doi: 10.1074/jbc.M805846200 PMID: 19158079

51. Broderick MJ, Winder SJ. Spectrin, alpha-actinin, and dystrophin. Adv Protein Chem 2005; 70: 203–246. PMID: 15937517

52. Bhasin N, Law R, Liao G, Safer D, Ellmer J, Discher BM, et al. Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol 2005; 352 (4): 795–806. PMID: 16139300
53. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycha-Gaam EE, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343 (6254): 180–182. PMID:2404210

54. Sakamoto M, Yuasa K, Yoshimura M, Yokota T, Ikemoto T, Suzuki M, et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293 (4): 1265–1272. PMID:12054513

55. Harper SQ, Crawford RW, DelloRusso C, Chamberlain JS. Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Hum Mol Genet 2002; 11 (16): 1807–1815. PMID:12140183

56. Amann KJ, Renley BA, Ervasti JM. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J Biol Chem 1998; 273 (43): 28419–28423. PMID:9774469

57. Bhosle RC, Michele DE, Campbell KP, Li Z, Robson RM. Interactions of intermediate filament protein synemin with dystrophin and utrophin. Biochem Biophys Res Commun 2006; 346 (3): 768–777. PMID:16777071

58. Yamashita K, Suzuki A, Satoh Y, Ide M, Amano Y, Masuda-Hirata M, et al. The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b. Biochem Biophys Res Commun 2010; 391 (1): 812–817. doi:10.1016/j.bbrc.2009.11.144 PMID: 19945424

59. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009; 119 (3): 624–635. doi:10.1172/JCI36612 PMID: 19229108

60. DeWolf C, McCauley P, Sirorski AF, Winlove CP, Bailey AI, Kahana E, et al. Interaction of dystrophin fragments with model membranes. Biophys J 1997; 72: 2599–2604. PMID:9168035

61. Burkhard P, Stetefeld J, Strelkov SV. Coiled coils: A highly versatile protein folding motif. Trends Cell Biol 2001; 11 (2): 82–88. PMID:11166216

62. Legrand B, Giudice E, Nicolas A, Delalande O, Le Rumeur E. Computational study of the human dystrophin repeats: Interaction properties and molecular dynamics. PLoS One 2011; 6 (8): e23819. doi: 10.1371/journal.pone.0023819 PMID: 21901138

63. Delorenzi M, Speed T. An HMM model for coiled-coil domains and a comparison with PSSM-based predictions. Bioinformatics 2002; 18 (4): 617–625. PMID:12016059

64. Ponting CP. Novel domains in NADPH oxidase subunits, sorting nexins, and PtdIns 3-kinases: Binding partners of SH3 domains? Protein Sci 1996; 5 (11): 2353–2357. PMID:8931154

65. Legge GB, Martinez-Yamout MA, Hambly DM, Trinh T, Lee BM, Dyson HJ, et al. ZZ domain of CBP: An unusual zinc finger fold in a protein interaction module. J Mol Biol 2004; 343 (4): 1081–1093. PMID:15476823

66. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989; 338 (6212): 259–262. PMID:2493582

67. Suzuki A, Yoshida M, Yamamoto H, Ozawa E. Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain. FEBS Lett 1992; 308 (2): 154–160. PMID:1499724

68. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem 1995; 270 (45): 27305–27310. PMID:7592992

69. Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies KE, Ozawa E. ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum Mol Genet (2004) 13 (7): 693–702. PMID:14962982

70. Hnia K, Zouiten D, Cantel S, Chazalette D, Hugon G, Fehrentz JA, et al. ZZ domain of CBP: An unusual zinc finger fold in a protein interaction module. J Biol Chem 2004; 343 (4): 1081–1093. PMID:15476823

71. Huang X, Poy F, Zhang R, Joachimiak A, Sudol M, Eck MJ. Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol 2000; 7 (8): 634–638. PMID:10932245

72. Tokarz SA, Duncan NM, Rash SM, Sadeghi A, Dewan AK, Pillers DA. Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of duchenne muscular dystrophy. Mol Genet Metab 1998; 65 (4): 272–281. PMID:9889014

73. Desguerre I, Christov C, Mayer M, Zeiler R, Becane HM, Bastuji-Garin S, et al. Clinical heterogeneity of duchenne muscular dystrophy (DMD): Definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 2009; 4 (2): e4347. doi:10.1371/journal.pone.0004347 PMID:19194511
74. Moizard MP, Toutain A, Fournier D, Berret F, Raynaud M, Billard C, et al. Severe cognitive impairment in DMD: Obvious clinical indication for Dp71 isoform point mutation screening. Eur J Hum Genet 2000; 8 (7): 552–556. PMID: 10909857

75. Becker K, Robb SA, Hatton Z, Yau SC, Abbs S, Roberts RG. Loss of a single amino acid from dystrophin resulting in duchenne muscular dystrophy with retention of dystrophin protein. Hum Mutat 2003; 21 (6): 651.

76. Sommer SS. Recent human germ-line mutation: Inferences from patients with hemophilia B. Trends Genet 1995; 11 (4): 141–147. PMID: 7732592

77. Kondrashov AS. Direct estimates of human per nucleotide mutation rates at 20 loci causing mendelian diseases. Hum Mutat 2003; 21 (1): 12–27. PMID: 12497628

78. Krawczak M, Ball EV, Cooper DN. Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. Am J Hum Genet 1998; 63 (2): 474–488. PMID: 9683596

79. Consortium CSaA. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 2005; 437 (7055):69–87. PMID: 16136131